176,969 BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 14.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,072,802 shares of the biotechnology company’s stock after selling 176,969 shares during the period. Pictet Asset Management Holding SA owned about 0.42% of BioCryst Pharmaceuticals worth $8,874,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BCRX. Alps Advisors Inc. grew its holdings in BioCryst Pharmaceuticals by 6.5% during the 3rd quarter. Alps Advisors Inc. now owns 338,545 shares of the biotechnology company’s stock worth $2,820,000 after acquiring an additional 20,585 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $133,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $109,000. Vise Technologies Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $181,000. Finally, State of Wyoming acquired a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $672,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $7.61 on Monday. The stock has a 50 day moving average price of $8.23 and a 200 day moving average price of $8.78. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -5.36 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.23 and a 52-week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $180.29 million for the quarter, compared to analysts’ expectations of $165.67 million. BioCryst Pharmaceuticals had a negative net margin of 37.40% and a negative return on equity of 92.91%. The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the company earned $0.06 earnings per share. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the subject of several recent analyst reports. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Weiss Ratings lowered BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. JPMorgan Chase & Co. raised their price target on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Wednesday, September 30th. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.38.

Check Out Our Latest Report on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Profile

(Free Report)

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.

Read More

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.